Short-Acting B2 Agonists Market 2026 witnessing steady respiratory care demand

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Short-Acting B2 Agonists Market During 2026–2030?

The short-acting b2 agonists market has experienced steady growth in recent years. It is projected to expand from $4.4 billion in 2025 to $4.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.1%. Historically, this expansion has been influenced by a high prevalence of asthma, the need for emergency respiratory care, the demand for fast-acting bronchodilators, existing hospital-based treatment protocols, and the availability of generic drugs.

The short-acting b2 agonists market is projected to experience consistent expansion over the upcoming years. It is anticipated to reach $5.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.2%. This expansion during the forecast period stems from factors such as increased air pollution, the rising burden of urban respiratory diseases, the growing adoption of home inhalers, an increase in pediatric asthma instances, and the broadening of outpatient respiratory care services. Key trends influencing the market during this period encompass its ongoing application as a primary rescue medication, the increasing prevalence of asthma and COPD, a preference for delivery methods based on inhalation, the expansion of respiratory treatments provided at home, and the wider availability of generic SABA products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24396&type=smp

What Underlying Factors Are Accelerating The Growth Of The Short-Acting B2 Agonists Market?

The escalating incidence of chronic obstructive pulmonary disease (COPD) is set to propel the expansion of the short-acting B2 agonists market in the coming years. COPD is a long-term respiratory ailment characterized by breathing difficulties and reduced airflow, primarily resulting from extended exposure to detrimental gases or cigarette smoke. The surge in COPD cases is attributed to heightened exposure to air pollution, as prolonged inhalation of contaminants like particulate matter and toxic gases can damage lung tissue and accelerate the disease’s progression. Short-acting ß2-agonists (SABAs) are utilized in COPD to provide swift relief from symptoms such as shortness of breath by relaxing airway muscles. They function as emergency medications during acute exacerbations but are not intended for ongoing management. For example, in December 2023, a research study published by JAMA Network Open, a medical journal by the American Medical Association, projected that the global burden of chronic obstructive pulmonary disease (COPD) could lead to nearly 600 million cases worldwide by 2050, signifying a 23% increase in prevalence. Thus, the rising prevalence of chronic obstructive pulmonary disease is expected to invigorate the growth of the short-acting B2 agonists market.

How Are The Various Segments Of The Short-Acting B2 Agonists Market Categorized?

The short-acting b2 agonists market covered in this report is segmented –

1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types

2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

3) By Administration Route: Inhalation, Oral, Injection

4) By End User: Hospitals, Clinics, Home Healthcare Settings

Subsegments:

1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups

2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions

3) By Metaproterenol: Inhalers, Syrups

4) By Other Types: Terbutaline, Pirbuterol, Salbutamol

What Trends Are Affecting The Expansion Of The Short-Acting B2 Agonists Market?

Major companies in the short-acting B2 agonists market are primarily focused on the development of technologically advanced products, such as pressurized metered-dose inhalers (pMDI), aimed at efficiently managing acute symptoms. Pressurized metered-dose inhalers (pMDIs) are portable devices that deliver a precise dose of medication to the lungs as an aerosol, propelled by a spray, and are commonly utilized for treating respiratory ailments like asthma and COPD. For instance, in January 2023, AstraZeneca, a UK-based pharmaceutical and biotechnology company, announced the US Food and Drug Administration (FDA) approval of Airsupra (albuterol/budesonide). Airsupra is a pioneering pressurized metered-dose inhaler (pMDI) that combines two active ingredients in a fixed-dose formulation: albuterol, a short-acting beta2-agonist (SABA) for quick bronchodilation, and budesonide, an inhaled corticosteroid (ICS) for reducing inflammation. This distinct combination is approved in the US for the as-needed treatment and prevention of bronchoconstriction in adults with asthma. Additionally, it contributes to lessening the risk of exacerbations, providing a comprehensive approach to asthma management.

Which Major Firms Influence Developments In The Short-Acting B2 Agonists Market?

Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.

Read the full short-acting b2 agonists market report here:

https://www.thebusinessresearchcompany.com/report/short-acting-b2-agonists-global-market-report

Which Region Is Projected To Dominate The Short-Acting B2 Agonists Market During The Forecast Period?

North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Short-Acting B2 Agonists Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24396&type=smp

Browse Through More Reports Similar to the Global Short-Acting B2 Agonists Market 2026, By The Business Research Company

Dopamine Agonists Market Report 2026

https://www.thebusinessresearchcompany.com/report/dopamine-agonists-global-market-report

Muscarinic Acetylcholine Receptor Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscarinic-acetylcholine-receptor-global-market-report

Glp 1 Receptor Agonist Market Report 2026

https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795